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Diabetic ketoacidosis (DKA) is a common and 
severe acute complication of diabetes mellitus. The 
annual incidence is 46 - 50 episodes per 10 000 
diabetic patients. DKA accounts for 14% of hospital 
admissions of diabetic patients and 10% of all deaths 
from diabetes in the Western world.[1] In sub-Saharan Africa the 
picture is bleaker, with mortality rates up to 30%.[2] It has been 
estimated that the annual cost of treating DKA in the USA exceeds 
1 billion USD[3] and that the average cost per DKA episode is 
USD6 500 - 7 500. This represented 25% of the total spent on the 
healthcare of patients with type 1 diabetes in 2010.[4] No published 
costing data are available from South Africa (SA).
When significant hyperglycaemia occurs, it is important to 
know whether it is accompanied by ketosis or ketoacidosis. High-
risk patients should be identified early, so that timely measures 
can be taken to prevent the significant morbidity and mortality 
associated with DKA. Ketone measurement allows the clinician to 
distinguish accurately between simple hyperglycaemia and metabolic 
decompensation with ketoacidosis, thus speeding up referral and 
management of patients with suspected DKA, when appropriate.
Urine dipstick testing for ketones (Ketostix) is the screening test 
currently widely used in our drainage area when DKA is suspected 
in patients with hyperglycaemia. It is used as a ‘surrogate’ because 
serum ketone and blood gas pH measurements are not readily 
available in most state health centres. However, the dipstick method 
has limitations. The test is based on the nitroprusside reaction, 
which gives a semiquantitative measurement of acetoacetate. It reacts 
weakly with acetone, but does not measure beta-hydroxybutyrate 
(β-OHB), and may give false-negative results. β-OHB is in fact the 
main metabolic product in the setting of DKA. It reflects the degree 
of ketosis, as levels of β-OHB correlate better than acetoacetate with 
falls in pH and bicarbonate levels. Early detection has been shown to 
lead to improved patient outcomes.[5] Tests based on the nitroprusside 
reaction have also been reported to give false-positive results in 
various clinical scenarios such as the fasting state, pregnancy and 
the use of sulphydryl-containing medications, e.g. angiotensin-
converting enzyme inhibitors.[6] In a position statement, the American 
Diabetes Association (ADA) emphasises that urine ketone tests are 
not reliable for diagnosing DKA and that measurement of β-OHB 
in blood is preferred for diagnosis.[7] At present, if urinary ketones 
are positive, these patients are referred to secondary or tertiary 
facilities for further management. This results in large numbers of 
patients being referred inappropriately as having DKA. Uncontrolled 
hyperglycaemia in the presence of a β-OHB level of >3.0 mmol/L 
indicates unequivocal DKA,[8] whereas a level of <1 mmol/L excludes 
any significant ketosis.[9]
Quantitative β-OHB measurement is unfortunately not offered 
by the routine laboratory at Tygerberg Hospital (TBH), Cape Town, 
SA (a tertiary academic training hospital). Samples are referred 
across town to the Red Cross War Memorial Children’s Hospital 
(RCWMCH) laboratory, and results are reported within 2 - 3 days. 
As a result, values cannot be used for decision-making in a medical 
emergency setting. Quantitative serum β-OHB measurement on 
a point-of-care testing (POCT) device has the potential to negate 
inappropriate referrals, which may translate into large cost savings 
if incorporated in initial patient assessment. It would also identify 
the ‘false negatives’ missed on Ketostix testing. POCT provides an 
attractive alternative to our current practice. Prior to its clinical use, 
it is essential that the POCT be evaluated to determine whether the 
device is accurate and precise and therefore fit for purpose. The 
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Background. Urine dipstick testing for ketones is widely used when diabetic ketoacidosis (DKA) is suspected in patients with hyperglycaemia. 
If urinary ketones are positive, patients are referred for further management – often inappropriately, as the test is a poor surrogate for plasma 
ketones. Plasma beta-hydroxybutyrate (β-OHB) levels >3 mmol/L are diagnostic of DKA, while levels <1 mmol/L are insignificant.
Objectives. To evaluate a hand-held electrochemical (point-of-care testing; POCT) ketone monitor and compare it with the gold-standard 
manual enzymatic method (MEM) for detection of plasma ketones.
Methods. In a prospective and comparative study, we evaluated the measurement of β-OHB by means of POCT and the MEM in 61 consecutive 
samples from patients with suspected DKA at Tygerberg and Karl Bremer hospitals, Cape Town, South Africa. Capillary (for POCT) and 
plasma samples (for the MEM) were obtained simultaneously and compared for accuracy. Precision was assessed with control samples.
Results. The POCT method was precise (coefficient of variation <4.5%), and there was a good correlation between the two methods 
(r=0.95). Regression analysis showed a proportional bias, with POCT reading higher than the MEM. However, when assessed at the relevant 
medical decision limits (β-OHB >3 mmol/L and <1 mmol/L), the total allowable error (bias + imprecision) was not exceeded. Patients will 
therefore still be classified correctly. The POCT method had a sensitivity of 100% and specificity of 89% for DKA (β-OHB >3 mmol/L), 
while at levels <1 mmol/L sensitivity was 100% and specificity 87.5%.
Conclusion. The POCT device provides an accurate and precise result and can be used as an alternative to the MEM in the diagnosis of DKA.
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Clinical and Laboratory Standards Institute 
(CLSI) has published guidelines to facilitate 
this evaluation process.
Objectives
(i) To evaluate a hand-held electrochemical 
(POCT) ketone monitor (Medisense/Abbott 
Optium Xceed) and compare it with the 
manual enzymatic method (MEM), the 
current gold standard, to assess its accuracy 
and precision; (ii) to assess diagnostic 
performance of the POCT v. the MEM; and 
(iii) to calculate possible cost implications 
of utilising POCT as an alternative to the 
MEM.
Methods
Study design and setting
The study was prospective and comparative, 
evaluating the measurement of β-OHB 
by means of electrochemical POCT and 
the MEM in consecutive patients referred 
from primary levels of care with suspected 
DKA. Referral was based on hyperglycaemia 
(capillary glucose >13.9 mmol/L) and the 
presence of urinary ketones on dipstick 
testing.
The study was conducted over a 4-month 
period in the acute medical admission ward 
and the high-care ward at TBH as well as in 
the acute medical admission ward at Karl 
Bremer Hospital (KBH), also in Cape Town. 
Blood samples were collected at admission and 
during treatment to ensure that a wide range of 
ketone values would be obtained. Patients were 
assessed clinically and attempts were made to 
identify the precipitant of the DKA episode.
Analytical performance
Method validations are performed to assess 
the degree of error inherent in a method and 
to determine whether the inaccuracy/bias 
and imprecision of the method will affect 
the interpretation of a test. CLSI documents 
EP09[10] (‘Method comparison and bias 
estimation using patient samples’) and 
EP15[11] (‘User verification of performance 
for precision and trueness’) (www.clsi.org) 
were followed. These documents state that 
precision can be determined using quality 
control samples, and that accuracy can be 
assessed by analysing at least 40 samples 
spanning the measurement range.
POCT was performed using the 
Medisense/Abbott Optium Xceed β-OHB 
meter, and results were expressed in 
mmol/L. Laboratory testing was performed 
by means of a MEM, results being expressed 
in µmol/L and then converted to mmol/L. 
The investigators were blinded to the results.
For precision studies, quality control 
samples at two levels close to the medical 
decision limits were provided by the 
manufacturer. Samples were analysed in 
triplicate over a 5-day period on the POCT 
device. The mean, standard deviation (SD) 
and coefficient of variation (CV, %) (mean/
SD × 100) were calculated and compared 
with the manufacturer’s published results as 
per the package insert. The manufacturer 
claims a total imprecision of 8.8% at a β-OHB 
level of 0.7 mmol/L and a total imprecision 
of 3.1% at a β-OHB level of 4.3 mmol/L.[12]
Accuracy studies were performed on 
61 samples collected from the 41 patients 
enrolled in the study. Samples from 
consecutively presenting patients were 
used with ketone levels that spanned 
the measurement range and included 
clinical decision-making levels. Capillary 
and serum samples were obtained at the 
same time. Capillary blood was used for 
POCT. Venous whole blood was collected 
in lithium heparin tubes (BD Vacutainer) 
and immediately transported on ice to the 
TBH National Health Laboratory Service 
(NHLS) laboratory. The transit time ranged 
from 10 to 20 minutes. At the laboratory, 
samples were immediately deproteinised 
with per chloric acid as per the RCWMCH 
protocol, stored at –70oC and transported 
to RCWMCH within 48 hours. At the 
RCWMCH laboratory the samples were 
stored at –20oC and analysed between 1 and 
7 days of arrival. According to the literature, 
plasma samples are stable for several weeks 
at –20oC.[13]
Linear regression analysis and a Bland-
Altman plot were used for analytical 
comparison and for depicting allowable 
bias and total allowable error. Method 
comparison statistics was performed with 
the Analyse-It version 2.3 data package for 
Excel.
Diagnostic performance
Sensitivity and specificity were calculated 
at the clinical decision-making limits 
(1  mmol/L and 3 mmol/L) to assess diag-
nostic performance.
Cost
The cost of reagent strips for POCT was 
borne by the manufacturer. The cost of the 
MEM was borne by the NHLS.
The cost for POCT is currently ZAR22 per 
strip, and the POCT device costs ZAR249. 
The cost of MEM for detection of serum 
ketones (including β-OHB + acetoacetate) 
is ZAR228.88.
Results
Demographics and descriptive 
parameters
Most patients seen at TBH and KBH are 
of mixed ancestry, the gender and ethnic 
distribution being representative of the 
general population served by these hospitals. 
In total, 61 samples were collected from 41 
patients, of whom 24 were females and 17 
males. The mean age was 33 years (range 17 - 
52). The majority had type 1 diabetes (n=29, 
70.7%), seven being newly diagnosed. All the 
patients were found to have ketones present 
on dipstick testing of the urine, ranging from 
1+ to 3+. Of the 41 referred patients with 
suspected DKA, only 15 were true DKA cases 
when using MEM ketones (>3 mmol/L) and 
hyperglycaemia (fingerprick blood glucose 
>13.9 mmol/L). The majority of the patients 
(n=26, 63.4%) were therefore inappropriately 
referred on the basis of positive urinary 
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Fig. 1. Precipitants of DKA.
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ketones and hyperglycaemia. When evaluating ketosis (β-OHB 
>1 mmol/L and <3 mmol/L), an additional five patients had ketosis 
but not ketoacidosis. Even if these five patients are added to the 15 
with DKA, more than half of all the patients (n=21, 51.2%) were 
inappropriately referred.
The factors that precipitated the DKA episodes are shown in 
Fig. 1. Although our study was not designed to investigate the causes 
thereof, it was clear that lack of adherence to insulin therapy and 
sepsis seemed to be the major contributors.
Analytical performance
Precision
Precision of POCT was assessed by adhering to guidelines of the 
CLSI.[14] A summary of the results is presented in Table 1. At both 
low and high control levels, the total imprecision of the POCT 
device did not exceed the imprecision claimed by the manufacturer. 
Manufacturer claims were therefore verified at both control levels.
Accuracy
As the data were not normally distributed, non-parametric statistics 
were used. Spearman rank order correlation, performed with regard 
to actual values in mmol/L of both results obtained from POCT and 
the MEM (Fig. 2), demonstrated a very high correlation between 
the two methods (r=0.95). Since high correlation coefficients do 
not imply agreement of methods, we examined the agreement using 
the Bland-Altman difference plot and depicting allowable bias 
(18.4%) and total allowable error (68.7%).[15] The Bland-Altman plot 
demonstrated a proportional bias, with the POCT device reading 
higher than the MEM. The bias exceeded the total allowable bias, 
but when combined with the precision, did not exceed the total 
allowable error (Fig. 3).[16] When assessed at medical decision limits, 
the positive bias was 0.22 mmol/L at 1 mmol/L (p=0.77) and 0.68 
mmol/L at 3 mmol/L (p=0.85).
Diagnostic performance
When compared with the MEM, the POCT device demonstrated a 
sensitivity of 100% and a specificity of 89.5% for diagnosing DKA 
(β-OHB >3 mmol/L) and a sensitivity of 100% and specificity of 
87.5% for excluding DKA (β-OHB <1 mmol/L) (Table 2). Other 
performance criteria are summarised in Table 2.
Discussion
DKA is a common complication in our diabetic population. It is 
clear that the majority of patients were inappropriately referred with 
suspected DKA, and that this might have been avoided had the means 
to detect serum ketones been available at referral centres.
Only a minority of patients had pH measurements before being 
referred. Is it then correct to diagnose DKA at a certain level of 
β-OHB (in an uncontrolled diabetic), without knowing the pH level? 
Ketone body anion concentrations directly reflect the rate of ketone 
body production, which is accompanied by equimolar production of 
Table 1. Manufacturer claims for precision of the POCT 
device validated using control samples
β-OHB, 
mmol/L Claimed CV, % Obtained CV, % Claim verified
0.7 8.8 4.3 Yes
4.3 3.1 2.3 Yes
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Fig. 2. Scatter plot showing correlation between the POCT method and the MEM.
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Fig. 3. Bland-Altman plot depicting allowable bias and total allowable error.
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hydrogen ions. Over the years numerous proposed markers and cut-
offs have confirmed that any diagnostic criterion for DKA is arbitrary. 
This led the ADA to issue a consensus statement in 2006 that included 
set levels of pH, HCO3, ketones, anion gap and glucose.[17] While all 
five of these criteria have serious limitations, the most robust criterion 
is regarded to be a serum bicarbonate level of <18 mEq/L. However, in 
a 2008 Mayo Clinic study comparing this cut-off level with appropriate 
levels of β-OHB, there was a statistically strong correlation overall, but 
16% false-positive and 17% false-negative rates at this bicarbonate 
level. Similarly, when a pH of <7.3 was the comparator, 20% of DKA 
patients had a false-negative pH.[8]
Although our study was not designed to investigate the causes of 
DKA, it was clear that lack of adherence to insulin therapy and sepsis 
seemed to be the major contributors. All the patients we evaluated 
were positive for urinary ketones on dipstick testing at the referring 
centres.
Measurement of urinary ketones has various limitations, especially 
in the diag nosis of DKA. Reliable quantitative serum ketone 
measurement is preferable. Measurement of serum ketones has many 
applications in the management of patients with diabetes. The need for 
a rapid, reliable and accurate method led to the development of POCT 
for the measurement of β-OHB. In our study we evaluated a hand-
held electrochemical POCT ketone monitor v. the MEM (current gold 
standard) and evaluated its use in a resource-limited setting.
The method validation performed in this study proved that POCT 
was precise and accurate. The POCT device did show a proportional 
bias (increase in the magnitude of the error as the test result increased), 
which exceeded the allowable bias as stated in the literature. However, 
when taking the low imprecision of the method into account, the total 
error did not exceed the total allowable error (bias + imprecision), 
making this method acceptable. The performance was also evaluated at 
the medical decision limits of 1 mmol/L (rule out DKA) and 3 mmol/L 
(rule in DKA). This confirmed that patients will not be incorrectly 
classified because of the observed bias. The POCT device was therefore 
deemed fit for purpose.
How should diabetic patients with β-OHB in the ketosis range be 
managed? Five of our patients had levels between 1 and 3 mmol/L 
with the MEM, and all five were also within this range on POCT. 
In general, it should therefore not be necessary to up-refer these 
patients. However, if such patients look unexpectedly ill or acidotic, 
they should be referred, as other factors such as lactic acidosis or 
renal failure may be present.
The current cost to user of performing a serum ketone test is 
ZAR228.88. This includes a serum qualitative ketone determination 
as well as acetoacetate and β-OHB quantitative determination. The 
cost of the POCT is ZAR22 per strip. For this study the point of care 
machine (Abbott OptiumXceed) was provided free of charge by the 
manufacturer. It retails for ZAR205 - 249. Even adding capital outlay, 
cost of disposables and sundries, it is clear that POCT is far more 
cost-effective than the MEM.
Study limitations
The aim of the study was to evaluate POCT in measuring blood 
ketones and not to ratify POCT for treatment monitoring. POCT was 
not incorporated in the decision-making in this study, so we cannot 
comment on its use to improve outcomes. Although use of POCT 
appears to be more economical than the MEM, a formal cost analysis 
was not performed. Consecutive patient samples were used for the 
method comparison, so the spread of results advised by the CLSI 
documents/Westgard Basic Method Validation guidelines[14] (which 
state that one-third of results must be in the low to low-normal range, 
one-third in the normal range, and one-third in the high-abnormal 
range) could not be followed.
Conclusions
The Abbot OptiumXceed POCT device prov ides an accurate and 
precise blood β-OHB result. This device offers a cost-effective practical 
alternative to laboratory measurement of ketones in patients with 
suspected DKA. Its adoption would bypass the use of urine dipstick 
testing to diagnose DKA, leading to more appropriate referrals and major 
cost savings. Our findings may potentially lead to better management 
of patients with DKA. However, appropriately designed studies will be 
needed to confirm this.
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Table 2. Ability of the POCT device to diagnose DKA and ketosis 
n/N (%)
DKA (β-OHB >3 mmol/L)
Sensitivity 23/23 (100.0)
Specificity 34/38 (89.5)
Positive predictive value 23/27 (85.2)
Negative predictive value 34/34 (100.0)
Ketosis excluded (β-OHB <1 mmol/L)
Sensitivity 33/33 (100.0)
Specificity 28/32 (87.5)
Positive predictive value 33/37 (89.2)
Negative predictive value 28/28 (100.0)
